Half-year report · Q2
2533.TEDINET S100WH6E
Period2025-01-01 → 2025-06-30
Filed2025-08-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥42.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥84.1bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥40.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | ¥2.3bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | ¥1.6bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.6bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.5bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.7bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.3bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | ¥1.3bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥53.9bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥55.7bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥56.0bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥28.4bn | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥31.3bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥25.5bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥24.5bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥23.3bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥802m | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥887m | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥797m | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥882m | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥982m | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥824m | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥377m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥495m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.2bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥752m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.9bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥414m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥32.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.39 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.81 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 45.7% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.4% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-06-30 | ¥49m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥44m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-06-30 | ¥6m |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥17m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥17m |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.5bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.5bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥568m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥39.1bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥39.0bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥12m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥1.4bn |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥660m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥660m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥389m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥42.2bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥42.2bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥12m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | ¥2.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-06-30 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-06-30 | ¥7m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥19m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥19m |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥363m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥37.4bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥37.4bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥14m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥903m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥567m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥567m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥298m |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥40.2bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥40.2bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥14m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 576
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | 1000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | 29000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | -7000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | -2000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | Prior1YTDDuration | -19000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | CurrentYTDDuration | -24000000 | JPY |
| Increase decrease in provision for share based remuneration for directors and other officers ope cf | Prior1YTDDuration | 11000000 | JPY |
| Increase decrease in provision for share based remuneration for directors and other officers ope cf | CurrentYTDDuration | -78000000 | JPY |
| Increase decrease in provision for shareholder benefit program ope cf | Prior1YTDDuration | -27000000 | JPY |
| Increase decrease in provision for shareholder benefit program ope cf | CurrentYTDDuration | -24000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -29000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -46000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 46000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 64000000 | JPY |
| Equity in earnings losses of affiliates ope cf | Prior1YTDDuration | -72000000 | JPY |
| Equity in earnings losses of affiliates ope cf | CurrentYTDDuration | -69000000 | JPY |
| Gain on sales of non current assets ope cf | Prior1YTDDuration | － | JPY |
| Gain on sales of non current assets ope cf | CurrentYTDDuration | -119000000 | JPY |
| Loss on sales and retirement of noncurrent assets ope cf | Prior1YTDDuration | 11000000 | JPY |
| Loss on sales and retirement of noncurrent assets ope cf | CurrentYTDDuration | 15000000 | JPY |
| Loss gain on cancellation of insurance contract ope cf | Prior1YTDDuration | － | JPY |
| Loss gain on cancellation of insurance contract ope cf | CurrentYTDDuration | 8000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | 692000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 1609000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -1126000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -371000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 184000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | -344000000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | Prior1YTDDuration | -419000000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | CurrentYTDDuration | -336000000 | JPY |
| Increase decrease in accrued liquor tax ope cf | Prior1YTDDuration | -172000000 | JPY |
| Increase decrease in accrued liquor tax ope cf | CurrentYTDDuration | -3130000000 | JPY |
| Other net ope cf | Prior1YTDDuration | -695000000 | JPY |
| Other net ope cf | CurrentYTDDuration | -670000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 1008000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | -33000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 94000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 197000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -62000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -83000000 | JPY |
| Proceeds from insurance income ope cf | Prior1YTDDuration | － | JPY |
| Proceeds from insurance income ope cf | CurrentYTDDuration | 80000000 | JPY |
| Income taxes paid refund ope cf | Prior1YTDDuration | -544000000 | JPY |
| Income taxes paid refund ope cf | CurrentYTDDuration | -538000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 495000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -377000000 | JPY |
| Purchase of noncurrent assets inv cf | Prior1YTDDuration | -706000000 | JPY |
| Purchase of noncurrent assets inv cf | CurrentYTDDuration | -1234000000 | JPY |
| Proceeds from sales of noncurrent assets inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from sales of noncurrent assets inv cf | CurrentYTDDuration | 182000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |